期刊文献+

四环素基因调节系统下小鼠VEGF基因表达效率的测定 被引量:1

Repression of VEGF expression in mouse tissues using tetracycline gene regulation system
下载PDF
导出
摘要 为了测定四环素基因调节小鼠模型的有效性和潜在的应用价值,针对各组织中VEGF mRNA表达水平受四环素调节的效率进行了分析.从小鼠不同组织提取总RNA,进行realtime PCR分析,并利用相对定量2-△△CT方法分析这些组织中VEGF基因在mRNA表达水平上的差异,同时观察和统计小鼠组织发育情况.结果表明,转基因小鼠体内各个组织的VEFG mRNA表达水平普遍下降,尤以脂肪和卵巢最为明显.其中心脏VEFG mRNA下降53%,肝脏下降72%,肺下降50%,血小板下降49%,肾脏下降44%,脑下降55%,脂肪下降90%,子宫下降52%,卵巢下降80%.同时VEGF基因表达下降导致小鼠各个相应组织器官的发育大小出现异常.因此,四环素基因调节系统能够有效地调节转基因小鼠各个组织VEGF基因的表达水平. Repression efficiency of mouse VEGF mRNA expression in tetracycline gene regulation system was evaluated.Total RNA was isolated from different mouse tissues including heart,liver,lung,kidney,brain,fat,uterus,ovary from double transgenic mice(VEGFteto/teto/βAtKtg/+) with or without tetracycline treatment.VEGF messages were measured by real time quantitative PCR.The data were analyzed using the 2-△△CT method.Results show that,after removal of tetracycline,the expression of VEGF gene was down regulated by 53% in heart,72% in liver,50% in lung,49% in platelet(data published),44% in kidney,55% in brain,90% in fat,52% in uterus,and 80% in ovary.Most organs showed significant weight loss with repression of VEGF.All above show that the tetracycline significantly regulated the VEGF mRNA expression in all the examined tissues,most dramatically down regulated in adipose tissue and ovary,accompanied with correspondingly morphological and functional disorders.
出处 《东北师大学报(自然科学版)》 CAS CSCD 北大核心 2011年第1期122-126,共5页 Journal of Northeast Normal University(Natural Science Edition)
基金 国家自然科学基金资助项目(30770493)
关键词 四环素基因调节系统 VEGF MRNA表达 REAL TIME PCR 组织发育 tetracycline gene regulation system VEGF mRNA level realtime quantitative PCR tissue development
  • 相关文献

参考文献10

  • 1FERRARA N, HENZEL W J. Pituitary follicular cells secrete a novel heparin binding growth factor specific for vascular endothelial cells [J]. Biophysical Research Communication, 1989 (2) : 851.
  • 2HIROYUKI TAKAHASHI,MASABUMI SHIBUYA. The vascular endothelia growth factor/VEGF receptors system and its role under physiological and pathological conditions [J]. Clinic Science, 2005 ( 109) : 227-241.
  • 3JAN1CE A NAGY, ANN M DVORAK, HAROLD F DVORAK. VEGFA and the induction pathological angiogenesis [J]. Annual Review Pathology Mechanisms of Disease,2007(2) ,251-275.
  • 4LEUNG D W,CACHIANES G,KUANG W J,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen [J]. Science, 1989(246), 1306-1309.
  • 5朱芷葳 赫晓燕 姜俊兵 等.RealtimePCR将成为分子生物学研究的重要检测技术.农业生物技术学报,:85-87.
  • 6KENNETH J LIVAK, THOMAS D SCHMITTGEN. Analysis of relative gene expression data using real time quantitative PCR and the 2^-△△CT method [J]. Methods,2001(25):402-408.
  • 7FERRARA N,CARVER-MOORE K,CHEN H,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J]. Nature, 1996,380(6573) :439-442.
  • 8CARMELIET P, FERREIRA V, BREIER G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J]. Nature,1996,380(6573):435-439.
  • 9姚瑞芹,李林.血管内皮细胞生长因子在缺血性脑损伤中血管新生、神经发生和神经保护的作用[J].中国康复理论与实践,2007,13(3):208-211. 被引量:14
  • 10沈诚,范士志,蒋耀光.血管内皮细胞生长因子及临床应用策略[J].国外医学(分子生物学分册),2003,25(1):6-9. 被引量:7

二级参考文献53

共引文献19

同被引文献17

  • 1王勇,王峰超,魏泓,倪勇,吴军,高翔.皮肤组织特异性表达hCTLA4-Ig转基因小鼠品系的建立[J].Acta Genetica Sinica,2005,32(9):916-922. 被引量:3
  • 2Arindel S R, Patricia A D. Roles forVEGF in adult [J]. Microvasc Res, 2007, 74 (2): 100-113.
  • 3Gentile C, Muise-Helmerieks R C, Drake C J. VEGF-mediated phosphorylation of eNOS regulates angiublast and embryonie endothe- lial cell proliferation [J]. Dev Biol, 2013, 373 ( 1 ) : 163-175.
  • 4Ren X, Ustiyan V, Pradhan A, et al. FOXFI transcription factor is required for formation of embryonie vaseulature by regulatingVEGF signaling in endothelial cells [J]. Circ Res, 2014, 115 (8) : 709 -720.
  • 5Eremina V, Jefferson J A, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy [ J ]. New Engl J Med, 2008, 358 (11): 1129-1136.
  • 6Gerber H P, Wu X, Yu L, eL al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti- VEGF antibodies [J]. Proc Nad Acad Sci USA, 2007, 104 (9) : 3478 -3483.
  • 7lnglis D J, Lavranos T C, Beaumont D M, et al. The vascular dis- rupting agent BNC105 potentiates the efficacy of VEGF and roTOR inhibilors in renal and breast cancer [ J ]. Cancer Biol Ther, 2014, 15 (11): 1552-1560.
  • 8Morita A, Nakahara T, Ushikuho H, et al. Treatment of newborn mice with inhibitors of vascular endothelial growth factor receptor lyrosine kinase induces abnomlal retinal vascular Datleming [ J ]. Bi- ol Pharm Bull, 2014, 37 (12): 1986-1989.
  • 9Kraeva N, lshemgulova A, Luke JBet al. Tetracycline-inducible gene expression system in Leishmania Mexicana [ J ]. Mol Biochem Parasitol, 2014, 198 (1) : 11-13.
  • 10Hosseini S J, Zomorodipour A, Jalal R, el al. A study of the expres- sion of functional human coagulation factor IX in keratinocytes using a nonviral vector regulated by KI4 promoter [ J ]. Appl Biochem Biotechnol, 2010, 162 (6): 1599-1611.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部